Literature DB >> 12810353

Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats.

S D Satoskar1, D E Keyler, M G LeSage, D E Raphael, C A Ross, P R Pentel.   

Abstract

Vaccination of rats against nicotine reduces nicotine distribution to brain even at nicotine doses greatly exceeding the estimated binding capacity of the available antibody. This observation suggests a differential effect by which vaccination reduces nicotine distribution to brain to a greater extent than to other tissues. To test this hypothesis, vaccinated rats received a single intravenous nicotine dose equal to twice the estimated binding capacity of nicotine-specific antibody in vaccinated rats. The total and bound serum nicotine concentrations were higher in the vaccinated rats compared to controls, while the unbound serum nicotine concentration was lower. Distribution of nicotine to brain was reduced in vaccinated rats in a time-dependent manner, with a greater reduction at 1 min (64%) than at 25 min (45%). Vaccination reduced nicotine distribution to muscle, testis, spleen, liver, heart, and kidney, but to a lesser extent than to brain, while nicotine distribution to fat was increased. Chronically infused nicotine showed a similarly altered pattern of tissue distribution in vaccinated rats, but differences were in general smaller than after a single nicotine dose; brain nicotine concentration was 24% lower in vaccinated rats, while lung nicotine concentration was higher. The presence of nicotine-specific antibody in tissues may have contributed to the increased nicotine concentrations in fat and lung. These data suggest that vaccination reduces nicotine distribution to brain not only by sequestering nicotine in serum but also by redirecting tissue distribution disproportionately away from brain, such that nicotine concentrations are reduced to a greater extent in brain than in other tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810353     DOI: 10.1016/S1567-5769(03)00094-8

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

Review 1.  Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.

Authors:  Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

2.  Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs.

Authors:  Nina Lindblom; Sabina H L de Villiers; Svetlana Semenova; Genadiy Kalayanov; Sandra Gordon; Björn Schilström; Anette M Johansson; Athina Markou; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-15       Impact factor: 3.000

3.  Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Authors:  Katherine E Cornish; Andrew C Harris; Mark G LeSage; Dan E Keyler; Danielle Burroughs; Cathy Earley; Paul R Pentel
Journal:  Int Immunopharmacol       Date:  2011-07-28       Impact factor: 4.932

Review 4.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

5.  A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.

Authors:  Kyle Saylor; Chenming Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-26       Impact factor: 4.219

6.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

7.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

8.  Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.

Authors:  Irina Esterlis; Jonas O Hannestad; Evgenia Perkins; Frederic Bois; D Cyril D'Souza; Rachel F Tyndale; John P Seibyl; Dorothy M Hatsukami; Kelly P Cosgrove; Stephanie S O'Malley
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

Review 9.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

Review 10.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.